Immuron (STU:ANWA) FCF Yield % : -17.40 (As of May. 17, 2024)

View and export this data going back to 2019. Start your Free Trial

What is Immuron FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Immuron's Trailing 12-Month Free Cash Flow is €-2.22 Mil, and Market Cap is €12.52 Mil. Therefore, Immuron's FCF Yield % for today is -17.40%.

The historical rank and industry rank for Immuron's FCF Yield % or its related term are showing as below:

STU:ANWA' s FCF Yield % Range Over the Past 10 Years
Min: -41.02 Med: -14.46 Max: -3.57
Current: -17.4

During the past 9 years, the highest FCF Yield % of Immuron was -3.57%. The lowest was -41.02%. And the median was -14.46%.

STU:ANWA's FCF Yield % is ranked worse than
55.23% of 1557 companies
in the Biotechnology industry
Industry Median: -14.1 vs STU:ANWA: -17.40

Immuron's FCF Margin % for the quarter that ended in Dec. 2023 was -85.06%.

Immuron FCF Yield % Historical Data

The historical data trend for Immuron's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immuron FCF Yield % Chart

Immuron Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

FCF Yield %

Get a 7-Day Free Trial

-7.73

-12.26

-20.26

-17.48

Immuron Semi-Annual Data
	Jun15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
FCF Yield %	Get a 7-Day Free Trial												-23.13	-10.63	-10.95	-21.55	-25.41

Competitive Comparison of Immuron's FCF Yield %

For the Biotechnology subindustry, Immuron's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immuron's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immuron's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Immuron's FCF Yield % falls into.

Immuron FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Immuron's FCF Yield % for the fiscal year that ended in Jun. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-1.613	/	9.2258352
	=	-17.48%

Immuron's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-1.23	*	2	/	9.681432
	=	-25.41%

Immuron FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Immuron FCF Yield % Related Terms

Thank you for viewing the detailed overview of Immuron's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Immuron (STU:ANWA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immuron Ltd (STU:ANWA) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

IMRN:USA ANWA:Germany IMC:Australia

Address

Chapman Street, Unit 10, 25-37, Blackburn North, Melbourne, VIC, AUS, 3130

Website

https://www.immuron.com.au

Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

Immuron (STU:ANWA) Headlines

No Headlines